In light of the long-term constraints posed by the "dual carbon" objective, can digital technology emerge as a transformative solution for enterprises to embark on a sustainable development trajectory? The existing body of research has yet to reach a consensus. In order to shed further light on the intricate relationship between digital transformation and ESG performance of enterprises, this study empirically examines the mechanisms and boundaries through which digital transformation influences ESG performance, based on observational data from A-share manufacturing listed companies in Shanghai Stock Exchange and Shenzhen Stock Exchange spanning from 2011 to 2021. The findings demonstrate that digital transformation exerts a significant positive impact on the ESG performance of manufacturing enterprises. Mechanism analysis reveals that the enabling effect of digital transformation primarily enhances company transparency, thereby fostering continuous improvements in ESG performance among manufacturing enterprises. The performance expectation gap will give rise to the phenomenon of "stop-loss in time" and impede the promotional impact of digital transformation. Further investigation into industrial characteristics and industry competition intensity indicates that state-owned enterprises and those operating within highly competitive environments experience more pronounced effects of digital transformation on their ESG performance. This study expands the mechanism and boundary of digital transformation on ESG performance of manufacturing enterprises, and provides a new perspective for manufacturing enterprises to realize the collaborative transformation of digital and green.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11023589 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302029 | PLOS |
BMC Health Serv Res
January 2025
School of Medicine and Health Management, Huazhong University of Science and Technology, Wuhan, China.
Background: Uncertain times require healthcare entities to demonstrate strong leadership, develop digitalisation, and respond to change in a creative and flexible manner. Based on emerging new institutional theory, we developed and tested a model of how digital transformational leadership (DTL) affects digital intensity (DI) among healthcare entities through the mediating role of organisational agility (OA). In this article, we also examine the moderating role of the country in the studied relationship.
View Article and Find Full Text PDFJ Environ Manage
January 2025
Unit:School of Business and Economics, Universiti Putra Malaysia, Serdang, Selangor Darul Ehsan, 43400, Malaysia. Electronic address:
Climate change poses significant challenges, making low-carbon development an essential global trend. In this context, building a green brand has become a critical strategy for companies to enhance consumer loyalty and maintain competitiveness. This study explores how the digital economy shapes sports brand loyalty, focusing on a dataset of Chinese A-share listed companies from Shanghai and Shenzhen, spanning 2011 to 2020.
View Article and Find Full Text PDFJ Pathol Clin Res
January 2025
Else Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
J Neuroimaging
January 2025
Department of Radiology, Division of Neuroradiology, Johns Hopkins Medical Center, Baltimore, Maryland, USA.
Background And Purpose: Prolonged length of stay (LOS) following a stroke is associated with unfavorable clinical outcomes. Factors predicting LOS in medium vessel occlusion (MeVO), impacting up to 40% of acute ischemic stroke (AIS) cases, remain underexplored. This study aims to investigate the predictors of LOS in AIS-MeVO.
View Article and Find Full Text PDFChin Med J Pulm Crit Care Med
December 2024
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for resectable non-small cell lung cancer. Numerous trials have explored the use of ICIs, either as monotherapy or in combination with other therapies, in the neoadjuvant setting for stage I-III non-small cell lung cancer. Most trials have demonstrated neoadjuvant immunotherapy to be safe and to have remarkable efficacy, with a high pathological response rate and significantly improved event-free survival.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!